

DRL and Galena Biopharma in strategic partnership for NeuVax


B KRISHNA MOHAN

Hyderabad

DR Reddy's Laboratories Limited (DRL) and Oregon-based biopharmaceutical company Galena Biopharma, which is into commercialising and developing targeted oncology treatments, Wednesday announced a strategic partnership to develop and commercialise NeuVax (nelipepimut-S) in India.

NeuVax is a vaccine aimed at preventing recurrence of breast cancer in patients under remission.

Under the terms of the agreement, Galena will licence commercial rights of NeuVax to DRL for breast



Joint effort

■ Licensing & development terms are conditioned to an agreement on ancillary activities

■ This partnership with Dr Reddy's is consistent with its strategy to expand clinical utility of NeuVax

and gastric cancers. DRL will lead its development and help expand the scope of therapy by addressing a new patient population. "NeuVax promises to meet unmet need in breast cancer and gastric cancer patients especially due to late diagnosis for majority of the

patients in India and therefore may have high probability of relapse of the disease" said Alok Sonig, senior vice-president and head of India business (generics), DRL.

"This partnership with Dr Reddy's is consistent with its strategy to expand

clinical utility of NeuVax in unmet medical needs while simultaneously increasing the commercial footprint of the innovative cancer immunotherapy, said Mark J Ahn, president and chief executive officer of Galena Biopharma.

"Dr. Reddy's is a global pharmaceutical company with significant commercialisation and development expertise. The gastric cancer trial will add a significant indication to our pipeline for NeuVax, while doubling our potential patient population if approved," he said.

krishnamohan
@mydigitalfc.com

International Cooperation.